- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00002411
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35203
- Sorra Research Ctr / Med Forum
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85016
- Body Positive
-
-
California
-
Fresno, California, Forente stater, 93710
- Hill Top Research Inc
-
Los Angeles, California, Forente stater, 900276069
- AIDS Healthcare Foundation
-
Los Angeles, California, Forente stater, 90024
- UCLA Med Ctr / CARE BH-412 CHS
-
Los Angeles, California, Forente stater, 90073
- West Los Angeles VAMC
-
Sherman Oaks, California, Forente stater, 91403
- Sherman Oaks Hosp Research Institute
-
Torrance, California, Forente stater, 90502
- Harbor UCLA Med Ctr / Research and Educational Institute
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06504
- Yale New Haven Hosp / Nathan Smith Clinic
-
-
District of Columbia
-
Washington, District of Columbia, Forente stater, 20037
- GW Med Ctr / Clinical Trials Unit
-
-
Florida
-
Fort Lauderdale, Florida, Forente stater, 33308
- Med Alternatives
-
Fort Lauderdale, Florida, Forente stater, 33316
- Urgent Care Ctr
-
Miami, Florida, Forente stater, 33142
- Specialty Med Care Ctrs of South Florida Inc
-
Tampa, Florida, Forente stater, 33602
- Hillsborough County Health Dept
-
Tampa, Florida, Forente stater, 33602
- Saint Josephs Hosp
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern Univ / Div of Infect Diseases
-
Chicago, Illinois, Forente stater, 60612
- Rush Presbyterian / ST Lukes Med Ctr
-
-
Kansas
-
Wichita, Kansas, Forente stater, 67214
- Univ of Kansas School of Medicine / Office of Rsch
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 405360226
- Ky Clinic Annex #4 / Room 205E / Speed Sort #0284
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Dartmouth-Hitchcock Med Ctr
-
-
New Jersey
-
Newark, New Jersey, Forente stater, 07103
- NJCRI
-
Somerville, New Jersey, Forente stater, 08876
- Infectious Disease Assoc of Central Jersey
-
-
New York
-
Farmingdale, New York, Forente stater, 11735
- UCT International
-
New York, New York, Forente stater, 10011
- St Luke Roosevelt Hosp
-
Rochester, New York, Forente stater, 14642
- St Mary's Hosp (Univ of Rochester/Infectious Diseases)
-
Stony Brook, New York, Forente stater, 117948153
- SUNY at Stony Brook / Div of Infectious Disease
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28207
- Nalle Clinic / Clinical Research Dept
-
-
Oklahoma
-
Tulsa, Oklahoma, Forente stater, 74114
- Associates in Med and Mental Health
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Stephen P Hauptman
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Med Univ of South Carolina / Div of Infect Disease
-
-
Texas
-
Galveston, Texas, Forente stater, 775550835
- Univ of Texas / Med Branch at Galveston
-
Houston, Texas, Forente stater, 77004
- Joseph C Gathe
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria
Patients must have:
Within 15 business days prior to randomization:
- CD4 cell count greater than or equal to 100 cells/mm3.
- HIV RNA greater than or equal to 2,000 copies/ml by Roche Amplicor Assay.
Exclusion Criteria
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
- Bilateral peripheral neuropathy.
- Intractable diarrhea.
- Proven or suspected acute hepatitis within 30 days prior to study entry.
Concurrent Medication:
Excluded:
- Therapy for any co-existing disease that may interfere with patient ability to participate in this study.
Concurrent Treatment:
Excluded:
Therapy for any co-existing disease that may interfere with patient ability to participate in this study.
Patients with the following prior conditions are excluded:
History of acute or chronic pancreatitis.
Prior Medication:
Excluded:
- Therapy for any previous disease that may interfere with patient ability to participate in this study.
- Excluded within 14 days prior to randomization:
Greater than 4 weeks of nucleoside therapy or greater than 1 week of protease inhibitor therapy.
- Excluded within 3 months of the start of this study or expected need at time of enrollment:
- Agents with significant systemic myelosuppressive, neurotoxic, pancreatoxic, hepatotoxic, or cytotoxic potential.
- Inability to tolerate oral medication.
Prior Treatment:
Excluded:
Therapy for any previous disease that may interfere with patient ability to participate in this study.
Risk Behavior:
Excluded:
Active alcohol or substance abuse that, in the opinion of the investigator, is sufficient to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Immunologiske mangelsyndromer
- Sykdommer i immunsystemet
- HIV-infeksjoner
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Revers transkriptasehemmere
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Anti-HIV-midler
- Antiretrovirale midler
- Antimetabolitter
- Proteasehemmere
- HIV-proteasehemmere
- Virale proteasehemmere
- Lamivudin
- Zidovudin
- Stavudine
- Didanosin
- Nelfinavir
Andre studie-ID-numre
- 039E
- AI454-148
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV-infeksjoner
-
Universidad del DesarrolloFullførtHealthcare Associated InfectionChile
-
Imelda Hospital, BonheidenFullførtHealthcare Associated InfectionBelgia
-
Centre Hospitalier Universitaire de NīmesRekrutteringEldre | Healthcare Associated InfectionFrankrike
-
Centre Hospitalier Universitaire, AmiensFullførtHealthcare Associated Infection | IglerFrankrike
-
Johns Hopkins UniversityFullførtHealthcare Associated Infection | Multiresistente organismer
-
University of PennsylvaniaFullførtAntimikrobiell resistensForente stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentFullførtMenneskelig mikrobiomForente stater
-
Universidad Autonoma de Nuevo LeonUkjentHelsetilknyttede infeksjoner
-
Children's Hospital Medical Center, CincinnatiAvsluttetAllogen hematopoetisk celletransplantasjonForente stater
-
Central Hospital, Nancy, FranceHar ikke rekruttert ennåHealthcare Associated Infection | Antibiotika
Kliniske studier på Lamivudin
-
Nanfang Hospital of Southern Medical UniversityGlaxoSmithKline; Major Science and Technology Special Project of China...FullførtKompensert kronisk hepatitt BKina
-
Glaxo WellcomeUkjentHIV-infeksjonerForente stater
-
ViiV HealthcareFullførtHIV-infeksjon | Infeksjon, humant immunsviktvirus IForente stater, Puerto Rico, Costa Rica, Panama
-
Fundación HuéspedViiV HealthcareFullførtHIV-1 infeksjonArgentina
-
Glaxo WellcomeFullført
-
ViiV HealthcareSyneos HealthAvsluttetHIV-infeksjonerTyskland, Spania, Forente stater, Canada, Frankrike, Italia, Sør-Afrika, Argentina, Portugal, Puerto Rico
-
ViiV HealthcareFullførtHIV-infeksjon | Infeksjon, humant immunsviktvirus IForente stater, Spania, Tyskland, Canada, Belgia, Portugal, Italia, Frankrike, Storbritannia
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...FullførtHIV-infeksjonerForente stater, Puerto Rico
-
Glaxo WellcomeFullført